We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
Total approvals
Agencies
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No approval data available
- The FDA issued an alert on August 27 identifying at least 30 patients who experienced adverse reactions after receiving intravenous glutathione from compounding pharmacies. - All affected pharmacies sourced their glutathione from Medisca Inc. lot 229536, which was labeled as dietary supplement grade rather than an appropriate injectable-grade ingredient. - Reported reactions include fever, chills, pain, dizziness, signs of shock, and sepsis-like symptoms, with some patients requiring hospitalization. - The agency has not approved any injectable glutathione product and continues to investigate adverse events consistent with endotoxin exposure.
